Compare · A vs RPID
A vs RPID
Side-by-side comparison of Agilent Technologies Inc. (A) and Rapid Micro Biosystems Inc. (RPID): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and RPID operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $37.48B, about 407.9x RPID ($91.9M).
- Over the past year, A is up 13.6% and RPID is down 43.6% - A leads by 57.2 points.
- A has been more active in the news (19 items in the past 4 weeks vs 17 for RPID).
- A has more recent analyst coverage (25 ratings vs 10 for RPID).
- Company
- Agilent Technologies Inc.
- Rapid Micro Biosystems Inc.
- Price
- $132.62-2.09%
- $1.99-0.25%
- Market cap
- $37.48B
- $91.9M
- 1M return
- +11.76%
- -22.61%
- 1Y return
- +13.55%
- -43.61%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2021
- News (4w)
- 19
- 17
- Recent ratings
- 25
- 10
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)
- President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)
- Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
- Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
- Director Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)
- SEC Form 10-Q filed by Agilent Technologies Inc.
- SEC Form SD filed by Agilent Technologies Inc.
- Agilent upgraded by BofA Securities with a new price target
- Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
- Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
Latest RPID
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)
- Director Malloy Kirk was granted 12,787 shares, increasing direct ownership by 27% to 60,687 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Wirtjes Sean M was granted 12,787 shares, increasing direct ownership by 2% to 568,981 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. was granted 12,787 shares, increasing direct ownership by 1% to 1,190,571 units (SEC Form 4)
- SEC Form SD filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Malloy Kirk was granted 19,300 shares, increasing direct ownership by 67% to 47,900 units (SEC Form 4)
- Director Lowenstein Inese was granted 19,300 shares, increasing direct ownership by 50% to 57,900 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 19,300 shares, increasing direct ownership by 28% to 87,900 units (SEC Form 4)